Covalent inhibitors, once sidelined due to concerns of irreversible toxicity and off-target reactivity, have re-emerged as a powerful strategy in modern drug discovery. Early successes such as aspirin and penicillin were discovered serendipitously, but the development of rationally designed agents like afatinib and ibrutinib, and more recently the clinical validation of KRAS^G12C inhibitors sotorasib and adagrasib, have transformed covalency from a taboo into a deliberate design principle. By forming persistent bonds, covalent inhibitors extend target engagement, enable lower dosing frequency, and unlock access to shallow or “undruggable” binding sites, while mass spectrometry and chemoproteomics provide robust tools for validation. Advances in warhead chemistry, ranging from acrylamides to nitriles, sulfonyl fluorides, and boronic acids along with electrophile-first libraries and proteomic profiling have enabled systematic, rational exploration of this modality. Protein kinases illustrate both promise and limitations: covalent EGFR and BTK inhibitors have delivered transformative therapies, yet noncovalent agents such as pirtobrutinib highlight that covalency is not always superior but context-dependent. Looking forward, diversification of amino acid targets, growth of reversible covalency, expansion into fields beyond oncology, and hybrid modalities such as covalent PROTACs will shape the next decade of discovery. Collectively, these developments underscore that the resurgence of covalent modulation is not simply a revival but a redefinition of therapeutic strategy, with risks that remain real yet outweighed by its potential as a cornerstone of future innovation.